Friends of Cancer Research has announced a new collaboration with global clinical research organisation, MMS, to develop decision frameworks that will help interpret interim overall survival (OS) data in oncology trials.
News
Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford
Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support...
FDA grants Breakthrough Therapy Designation to lung cancer therapy
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab...
Ogsiveo approved in EU for treatment of desmoid tumors
Merck’s therapy becomes first authorised option for aggressive soft tissue tumours
Upperton and Oxford join forces to develop oral vaccine formulation
Project aims to improve global immunisation through needle-free delivery
Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection
Mounjaro shows cardiovascular benefit in head-to-head diabetes trial
Lilly’s study finds tirzepatide delivers broader health improvements
FDA approves AJOVY for paediatric migraine prevention
Teva’s CGRP therapy becomes first approved option for children and adolescent
Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Promising results support global submissions and priority review by US FDA
Lilly’s Jaypirca shows positive results in phase 3 trial
Pirtobrutinib meets primary endpoint in CLL/SLL study
Lilly and UK Government launch £85 million obesity care innovation programme
Nationwide competition to pilot new models of obesity support
Sever Pharma expands work on ketamine implant with Silo Pharma
New phase of development targets chronic pain and fibromyalgia
Scotland approves zanubrutinib for relapsed mantle cell lymphoma
New treatment option now available across all UK nations
NICE backs KEYTRUDA combination for advanced endometrial cancer
New first-line option for patients with pMMR and dMMR tumours in England
FDA expands AVTOZMA IV approval to include cytokine release syndrome
Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US
